Effect of oral isotretinoin on dysplastic nevi

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Dysplastic nevi are atypical moles that can increase melanoma risk.
• Retinoids, vitamin A derivatives, have shown potential in cancer prevention.
• Previous studies indicated topical tretinoin may favorably affect dysplastic nevi histologically.

Purpose of the Study:

• To investigate the anticancer and cancer preventive effects of systemic retinoids.
• To evaluate the impact of oral isotretinoin on dysplastic nevi in patients with dysplastic nevus syndrome.

Main Methods:

• Eleven patients with dysplastic nevus syndrome received oral isotretinoin (40 mg twice daily for 4 months).
• Baseline biopsies were performed, followed by clinical assessment and repeat biopsies of selected lesions post-therapy.
• Histologic evaluation compared pre- and post-treatment appearances of dysplastic nevi.

Main Results:

• No significant clinical changes were observed in dysplastic nevi during or after isotretinoin treatment.
• Post-therapy biopsies showed that most remaining lesions were still dysplastic nevi.
• In two subjects, the majority of biopsied lesions were histologically normal benign nevi (28% overall), a rate not significantly different from historical controls.

Conclusions:

• Oral isotretinoin, at the dosage and duration used, did not demonstrate a significant biologic effect on the clinical or histologic characteristics of dysplastic nevi.
• The findings suggest that systemic isotretinoin is not effective for altering dysplastic nevi in the context of dysplastic nevus syndrome under this treatment regimen.